Infliximab
Lung Cancer
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 65/ 100
Competitive context
303 Active assets in the Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II University of Vermont | Phase 4 | BB |
Carboplatin SystImmune Inc. | Phase 4 | BB |
PROPOFOL Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 4 | BB |
Nivolumab University of Chicago | Phase 4 | BB |
ETOPOSIDE SystImmune Inc. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Infliximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →